Beacon Therapeutics

Beacon Therapeutics, a Syncona's portfolio company and formed following Applied Genetic Technologies Corp (AGTC)'s acquisition and other preclinical programs, including an in-licensed candidate from the University of Oxford, is a biotechnology company focused on developing gene therapies for the potential treatment of retinal diseases, including X-linked retinitis pigmentosa, dry age-related macular degeneration and cone-rod dystrophy.In October 2022, Syncona signed a definitive agreement to acquire Applied Genetic Technologies Corp (AGTC). The transaction would be expected to close in the fourth quarter of 2022, subject to customary closing conditions. In October 2022, AGTC and newly launched portfolio company of Syncona announced the commencement of previously announced tender offer for all the issued and outstanding shares of common stock of the company. In November 2022, Syncona extended the expiration of its tender offer to purchase all of the issued and outstanding shares of AGTC